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ABSTRACT 
 
Clinicopathological characteristics of cholangiocarcinoma:  
Comparison between cholangiolar differentiation and bile ductal 
differentiation 
 
Jung Eun Ko 
 
Department of Medical Science 
The Graduate School, Yonsei University  
 
(Directed by Professor Young Nyun Park) 
 
Recently intrahepatic cholangiocarcinoma (ICC) has been subclassified into 
cholangiolar differentiation and bile ductal differentiation; however their 
clinicopathological and molecular characteristics have not been fully understood. 
We studied 142 human ICC cases of Severance hospital from 1997 to 2013, and 
there were 20 cases (14.1%) of ICC with cholangiolar differentiation, and 122 cases 
(85.9%) of ICC with bile ductal differentiation. The expression of c-reactive protein 
(CRP), claudin 18 (CLDN18), N-cadnerin, Neural cell adhesion molecule (NCAM), 
vimentin, and epithelial-mesenchymal transition (EMT)-related markers (ZEB1, 
ZEB2, TWIST, SNAIL and loss of E-cadherin) were evaluated by 
immunohistochemistry or real-time PCR. The expression levels of these markers 
and clinicopathological features were compared between two groups. ICC patients 
with cholangiolar differentiation revealed higher incidence of female and viral 
hepatitis, and less incidence of hepatolithiasis, ductal epithelial dysplasia compared  
2 
 
 
to those with the ICC with bile ductal differentiation (P <0.05, for all). The mass-
forming gross type was found in all of ICCs with cholangiolar differentiation in 
contrast that it was detected in 72 cases (59%) of ICCs with bile ductal 
differentiation (P = 0.005). The ICCs with cholangiolar differentiation showed less 
perineural invasion compared to ICCs with bile ductal differentiation (P = 0.013). 
The protein expression of CRP, N-cadherin and NCAM was more frequently found 
in ICCs with cholangiolar differentiation compared to those with bile ductal 
differentiation (P < 0.05, for all). The protein expression of CLDN18 and ZEB1 
was more frequently detected in ICCs with bile ductal differentiation compared to 
those with cholangiolar differentiation (P < 0.05, for all). The protein expression of 
TWIST and E-cadherin loss showed no significant difference between two groups. 
The mRNA expression levels of SNAIL and ZEB1 were lower in ICCs with 
cholangiolar differentiation compared to ICCs with bile ductal differentiation (P 
<0.05, for both), whereas that of ZEB2 showed no significant difference between 
two groups. ICCs with cholangiolar differentiation showed better overall survival 
compared to ICCs with bile ductal differentiation (P = 0.021). ICCs with CRP 
expression or N-cadherin expression revealed better prognosis compared those 
without (P <0.05, for all). In conclusion, ICC with cholangiolar differentiation and 
ICC with bile ductal differentiation are suggested to be distinct based on 
clinicopathological characteristics. ICC with cholangiolar differentiation is 
considered to be less aggressive type of ICC with better prognosis compared to ICC 
with bile ductal differentiation. CRP and N-cadherin are suggested to be good 
markers for cholangiolar differentiation. 
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I. INTRODUCTION 
 
Cholangiocarcinoma (CC) is a malignancy of biliary epithelium, arises in any 
portion of biliary tree, including intrahepatic, perihilar, or distal extraheptic bile 
duct.
1-3
 The biologic behaviors, clinical characteristics of CC vary dependent on 
their anatomic location of origin.
4-6
 Especially, intrahepatic cholangiocarcinoma 
(ICC), which arises from the liver periphery, has distinct characteristics compared 
to the CC originated from large bile ducts; hilar or extrahepatic CC. ICC is often 
mass forming-type, more frequently associated with chronic liver parenchymal 
disease such as viral hepatitis and shows less perineural, lymphatic invasion 
compared to hilar CC.
5,7-11
  
Recently, ICC has been further classified as two categories based on its histological 
features: cholangiolar differentiation and bile ductal differentiation.
12-14
 The 
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cholangiolar differentiation is composed of cuboidal to low columnar tumor cells, 
resembling small bile duct of the liver, while bile ductal differentiation is composed 
of tall columnar tumor cells, similar to large bile duct. Interestingly, cholangiolar 
differentiation is associated with viral hepatitis while the bile ductal differentiation 
is associated with hepatolithiasis. ICC with bile ductal differentiation commonly 
expressed pancreatic cancer markers such as TFF1, AGR2 and S100P, and shows 
worse prognosis compared to cholanigolar differentiation. Taken together, 
according to the relevant morphologies, etiologies and molecular patterns, the ICC 
with cholangiolar differentiation is likely to originate from hepatic progenitor cells, 
while the ICC with bile ductal differentiation is similar to extrahepatic bile duct or 
pancreatic adenocarcinoma.
15,16
 Through this, ICC is heterogeneous group of tumor 
possessing various cellular origin and different processes for carcinogenesis.
10
 
Furthermore, several transcriptomic studies reported molecular subclasses for 
ICCs.
17,18
 CCs were largely grouped distinct classes with distinct gene expression 
profile and mutations; good and poor prognosis classes,
17
 and proliferation and 
inflammatory classes.
18
 The more aggressive classes, poor prognosis class and 
proliferation class, were associated with activation of oncogenic signaling such as 
EGF, MET, RAS, AKT and poor clinical outcome. In contrast, the less aggressive 
class, inflammatory class was characterized by activation of inflammatory signaling 
pathways, and good clinical outcome. 
Therefore, ICC is heterogeneous in its cellular origin, etiology, histologic feature, 
and molecular profile. However, this heterogeneity of ICC is not well understood. 
The biological background of the molecular classification and the relationship with 
histological subgroup of ICC is unknown; furthermore, clinicopathological 
characteristics in relation to microscopic findings have not been fully understood. 
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Therefore, we integratively analyzed the molecular signatures, clinicopathologic 
characteristics, and clinical outcomes according to the histological subgroup of ICC. 
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II. MATERIALS AND METHODS 
 
1. Case selection and histopathological examination 
 
We enrolled consecutive intrahepatic cholangiocarcinoma (ICC) patients who had 
undergone surgical resection from 1997 to 2013 in our institution. The cases 
without appropriate paraffin-embedded tissue or the cases that pretreated with any 
kind of preoperative treatment were excluded. The representative blocks of 
formalin-fixed and paraffin-embedded tissue were sectioned and stained with 
hematoxylin-eosin (H&E). ICCs were grouped in to cholangiolar differentiation and 
bile ductal differentiation according to the histologic features.
12,13
 This study was 
approved by the institutional review board of Severance Hospital (4-2014-0865) 
and the requirement for informed consent was waived.  
 
2. Tissue microarray construction 
 
Core tissue biopsies were taken from individual paraffin embedded 
cholangiocarcinoma donor blocks and arranged in recipient tissue-array blocks 
using a trephine apparatus (Beecher Instruments,Silver Springs, FL, USA). At least 
2 cores were sampled from each tumor, with the number of cores depending on the 
degree of heterogeneity present on histologic examination. 
 
3. Immunohistochemistry 
 
Four-micron thick tissue sections were deparaffinized with xylene and rehydrated 
with graded alcohols. After washing in distilled water, sections were immersed in 3% 
hydrogen peroxide to block endogenous peroxidase. Information on antibodies used 
and antigen-retrieval conditions are described in Table 1. Immunohistochemical 
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stain for NCAM, ZEB1, TWIST, and E-cadherin was performed using automated 
staining system (Ventana Medical Systems, Inc., Tucson, AZ, USA). CRP, 
CLDN18, N-cadherin and vimentin were performned using the DAKO Envision Kit 
(Dako) according to the manufacturer’s instructions. All slides were counterstained 
with hematoxylin. Brown membranous and/or cytoplasmic staining was counted as 
positive for CRP, CLDN18, NCAM, N-cadherin, vimentin, E-cadherin, and nuclear 
and/or cytoplasmic staining for ZEB1, TWIST was counted as positive. For all 
antibodies studied, except for NCAM, CRP, TWIST and E-cadherin, the 
immunohistochemical stain results were interpreted in a semiquantitative manner 
and given a score, from 0 to 3, as follows: 0: staining in <5% of tumor cells; 1: 
weak or moderate staining in >5%; 2: moderate or strong staining in ≥5%; and 3: 
moderate of strong staining in ≥50% of tumor cells. Positive staining was defined as 
staining scores of 2 and 3 whereas o and 1 were regarded as negative. For NCAM, 
positivity was defined as membranous expression in ≥1% of tumor cells with 
moderate or strong intensity. For CRP, positivity was defined as membranous 
expression in ≥50% of tumor cells with moderate or strong intensity. For TWIST, 
positivity was defined as nuclear expression in ≥3% of tumor cells with moderate or 
strong intensity. For E-cadherin, immunohistochemical scoring was performed as 
follows: 0: loss of membranous expression in ≤5%; 1: loss of membranous E-
cadherin expression in >3%. 
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Table 1.  List of antibodies used for the immunohistochemistry 
Antibody Source Dilution Antigen retrieval 
NCAM (mouse mAb clone 
123C3) 
Zymed (San Francisco, CA) 1:100 
Microwave, citrate 
(pH 6.0) 
N-cadherin (mouse mAb 
clone 3B9) 
Zymed (San Francisco, CA) 1:300 
Microwave, citrate 
(pH 6.0) 
ZEB1 (rabbit mAb clone 
D80D3) 
Cell signaling (Danvers, 
MA, USA) 
1:100 
Microwave, citrate 
(pH 6.0) 
E-cadherin (mouse mAb 
clone NCH-28) 
Dako (Glostrup, Denmark) 1:100 
Microwave, citrate 
(pH 6.0) 
TWIST (rabbit pAb) 
Santa Cruz Biotechnology 
(Santa Cruz, CA) 
1:50 
Microwave, citrate 
(pH 6.0) 
vimentin (mouse mAb clone 
Vim3B4) 
Dako (Glostrup, Denmark) 1:200 
Microwave, citrate 
(pH 6.0) 
CRP (rabbit pAb) 
Abcam  (Cambridge, MA, 
USA) 
1:1000 
Microwave, citrate 
(pH 6.0) 
CLDN18  (rabbit pAb) Sigma (St. Louis,MO, USA) 1:100 
Microwave, citrate 
(pH 6.0) 
Abbreviations: mAb, monoclonal antibody; pAb, polyclonal antibody; CRP, c-reactive 
protein; CLDN18, claudin 18 
 
 
4. Total RNA extraction, cDNA synthesis, and quantitative real-time reverse 
transcriptase PCR (qRT-PCR) 
 
Quantitative real-time RT-PCR was performed using fresh frozen tissues, which 
were available in 60 cases of ICC. Total RNA was isolated using Trizol reagent 
(Life Technologies, Gaithersburg, MD, USA) according to the manufacturer’s 
protocol. RNA pellet was dried and eluted using RNase-free water and purity was 
validated using gel electrophoresis and quantified with a spectrophotometer 
NanoDrop (Thermo Scientific, Wilmington, DE, USA). Complentary DNA 
synthesis was performed with TOPscript cDNA Synthesis kit (Enzynomics, 
Daejeon, Korea). Briefly, the reaction master mix containing 2× RT Buffer, 20× 
Enzyme Mix, and nuclease-free water was mixed with 1µg of each total RNA 
sample. The mixtures were incubated for 60 minutes at 37°C, 5 minutes at 95°C, 
and then kept at 4°C. Real-time quantitative RT-PCR was carried out using the 
Applied Biosystems Step-One plus Real-Time PCR System. All reagents for 
quantitative RT-PCR were purchased from Applied Biosystems. The TaqMan 2x 
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universal PCR Master mix, 20x TaqMan assay, and RT products in a 20μl reaction 
volume were processed as follows: 95°C for 10 minutes, 40 cycles of 95°C for 15 
seconds, and then 60°C for 60 seconds. The signal was collected at the endpoint of 
every cycle. The mean values of the Ct, obtained in triplicate, were used for data 
analysis. The Assay IDs of the primers were as follows: SNAIL (Hs00950344_a1), 
ZEB1 (Hs00232783_ml), ZEB2 (Hs00207691_ml) and GAPDH 
(Hs_99999905_m1). 
 
5. Statistical analyses 
 
Statistical analysis was performed using the IBM SPSS 20.0.0.1 (IBM Corporation, 
NY, USA) .We assessed the immunohistochemical stain results using the Chi-
square test, and a Mann-Whitney U test was used to compare the results of the real-
time quantitative RT-PCR. Survival analyses for disease-free survival and overall 
survival were carried out with Kaplan-Meier’s method and log-rank tests. A p-value 
of less than 0.05 was considered statistically significant for all analysis. 
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III. RESULTS 
 
1. Histological evaluation for ICCs with cholangiolar differentiation and ICCs 
with bile ductal differentiation 
 
Histological evaluation for ICCs with cholangiolar differentiation and those with 
bile ductal differentiation were performed according to the previous report.
12,13
 
Briefly, cell morphology of the cholangiolar differentiation is cuboidal, with 
eosinophilic or amphophilic cytoplasm while retaining glandular, micropapillary, 
solid or cribriform pattern, while the features for bile ductal differentiation are long 
shaped and mucinous cytoplasm, and desmoplastic stroma. All of ICCs 
demonstrated mixed cholangiolar and bile ductal differentiation. ICC showing more 
than 10% of tumor area with cholangiolar component was defined as ICC with 
cholangiolar differentiation, and the other case was defined as ICCs with bile ductal 
differentiation 
 
2. Comparison of clinicoparhological features between ICCs with cholangiolar 
differentiation and ICCs with bile ductal differentiation 
 
Approximately 14.1% (20/142) ICCs were grouped as ICCs with cholangiolar 
differentiation, and the remaining 85.9% (122/142) ICCs were ICCs with bile ductal 
differentiation, and the clinicopathological features were compared between ICCs 
with cholangiolar differentiation and ICCs with bile ductal differentiation (Table 2). 
The ICCs with cholangiolar differentiation were composed of higher proportions of 
female cases compared to the ICCs with bile ductal differentiation (P=0.028). ICCs 
with cholangiolar differentiation were frequently associated with viral hepatitis 
(HBV or HCV, defined by serological test, P=0.001), while ICCs with bile ductal 
differentiation were associated with hepatolithiasis (P=0.043), ductal epithelial 
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dysplasia (P=0.004). In serologic test, the ICCs with cholangiolar differentiation 
demonstrated lower carbohydrate antigen 19-9 (CA19-9) levels, compared to ICCs 
with bile ductal differentiation (P=0.002). However, the levels of 
carcinogembryonic antigen (CEA), alpha-fetoprotein (AFP), protein induced by 
vitamin K absence/antagonist-II (PIVKA-II) were not significantly different in two 
groups. The gross morphology was different according to the histologic subgroup. 
The mass-forming gross type was found in all of ICCs with cholangiolar 
differentiation in contrast that it was detected in 72 cases (59%) of ICCs with bile 
ductal differentiation (P=0.005). ICCs with cholangiolar differentiation showed less 
frequent perineural invasion, (P=0.013) and more frequent fibrous capsule 
formation (P=0.019). 
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Table 2. Comparison of clinicopathologic features of ICCs between 
cholangiolar differentiation and bile ductal differentiation 
Clinicopathologic features 
Cholangiolar 
differentiation  
(n=20) 
Bile ductal 
differentiation  
(n=122) 
P value* 
Age (years, median, IQR)  58 (55-69) 64 (57-69) 0.274 
Gender (Male, Female, %) 7 (35), 13 (65) 76 (62), 46 (38) 0.028 
Serum markers    
CA19-9 (U/mL, median, IQR) 8.8 (1.9-37.6) 30.6 (8.2-283) 0.002 
CEA (ng/mL, median, IQR) 2.4 (1.5-4) 2.1 (1.4-383) 0.614 
Alpha-fetoprotein 
(IU/mL,median, IQR) 
3.0 (1.6-5) 2.8 (2.1-5.1) 0.697 
PIVKA-II (mAU/mL, median, 
IQR) 
37.5 (24-40) 27.0 (19-35) 0.065 
Tumoral pathology    
Tumor size (cm, median, IQR)  5 (3.7-6.8) 5.0 (2.8-6) 0.186 
Gross morphology (%) 
  
0.005 
     Mass forming 20 (100) 72 (59) 
 
     Periductal infiltrating 0 8 (6) 
 
     Intraductal growth 0 19 (16)  
     Mixed 0 23 (19)  
Differentiation (%) 
  
0.071 
     Well differentiation 10 (56) 30 (26) 
 
     Moderate differentiation 7 (39) 62 (54) 
 
     Poor differentiation 1 (5) 20 (17) 
 
     Undifferentiation 0 3 (3) 
 
Fibrous capsule formation (present, %) 2 (10) 0 0.019 
Microvessel invasion (present, %) 12 (60) 80 (66) 0.623 
Bile duct invasion (present, %) 5 (25) 45 (37.2) 0.326 
Serosal invasion (present, %) 18 (90) 82 (67) 0.061 
Perineural invasion (present, %) 3 (15) 53 (46) 0.013 
Non-tumoral pathology    
Viral hepatitis (present, %) 10 (53) 17 (16) 0.001 
Hepatolithiasis (present, %) 0 22 (18) 0.043 
Ductal epithelial dysplasia (present, %) 0 36 (30) 0.004 
Abbreviations: IQR, interquartile range. 
*p-values were calculated by Fisher’s exact test, Pearson chi-square and Mann-Whitney U test. 
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On the basis of gross morphology, ICC is classified into three subtypes: mass-
forming type, periductal infiltrating type, and intraductal type.
19
 The periductal 
infiltrating and intraductal type tumor cells grow longitudinally along large bile 
ducts, while mass-forming type tumor cells grow along small bile duct in liver. 
Because mass-forming type tumor cells composed of cholangiolar and bile ductal 
components, we further analyzed the clinicopathologic features of mass-forming 
ICCs according to the histologic subgroup (Table 3). Similar to the result of whole 
ICC cases, mass-forming ICCs with cholangiolar differentiation were associated 
with female gender, background liver parenchymal disease, lower CA19-9 levels, 
less frequent preneural invasion, compared to mass-forming ICCs with bile ductal 
differentiation. (P<0.05 at all) In addition, mass-forming ICCs with cholangiolar 
differentiation demonstrated the better tumor differentiation, more fibrous capsule 
formation compared to mass forming ICCs with bile ductal differentiation (P<0.001, 
P=0.045, respectively). 
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Table 3. Comparison of clinicopathologic features of ICCs between mass-
forming ICCs with cholangiolar differentiation and mass-forming ICCs 
with bile ductal differentiation 
Clinicopathologic features 
Cholangiolar 
differentiation  
(n=20) 
Bile ductal 
differentiation  
(n=72) 
P value* 
Age (years, median, IQR)  58 (55-69) 63 (55-69) 0.526 
Gender (Male, Female, %) 7 (35), 13 (65) 48 (67), 24 (33) 0.019 
Serum markers    
CA19-9 (U/mL, median, IQR) 8.8 (1.9-37.6) 60.3 (14-950) 0.004 
CEA (ng/mL, median, IQR) 2.4 (1.5-4) 3.6 (1.6-11.9) 0.294 
Alpha-fetoprotein 
(IU/mL,median, IQR) 
3.0 (1.6-5) 2.9 (1.9-5.2) 0.852 
PIVKA-II (mAU/mL, median, 
IQR) 
37.5 (24-40) 27.0 (21-31) 0.076 
Tumoral pathology    
Tumor size (cm, median, IQR)  5 (3.7-6.8) 5 (3.3-6.5) 0.748 
Differentiation (%) 
  
<0.001 
     Well differentiation 10 (56) 3 (5) 
 
     Moderate differentiation 7 (39) 44 (65) 
 
     Poor differentiation 1 (5) 17 (25) 
 
     Undifferentiation 0 3 (5) 
 
Fibrous capsule formation (present, %) 2 (10) 0 0.049 
Microvessel invasion (present, %) 12 (60) 58 (81) 0.076 
Bile duct invasion (present, %) 5 (25) 19 (26) 1.000 
Serosal invasion (present, %) 18 (90) 59 (82) 0.509 
Perineural invasion (present, %) 3 (15) 21 (34) 0.009 
Non-tumoral pathology    
Viral hepatitis (present, %) 10 (53) 14 (23) 0.020 
Hepatolithiasis (present, %) 0 4 (6) 0.573 
Ductal epithelial dysplasia (present, %) 0 13 (18) 0.063 
Abbreviations: IQR, interquartile range. 
*p-values were calculated by Fisher’s exact test, Pearson chi-square and Mann-Whitney U test. 
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3. Comparison of CRP, N-cadherin, NCAM, CLDN18 and EMT-related 
marker expression between ICCs with cholangiolar differentiation and ICCs 
with bile ductal differentiation 
 
We compared the expression of the differentiation markers that we found in gene 
expression profiles (CRP, CLDN18), and previously reported cholangiolar/ductular 
differentiation markers (N-cadherin, NCAM, and vimentin).
7,13
 The CRP protein 
expression was more frequently observed in ICCs with cholangiolar differentiation, 
compared to ICCs with bile ductal differentiation (P<0.001, Figure 1A, B). In 
contrast, CLDN18 protein expression was more frequently found in ICCs with bile 
ductal differentiation compared to ICCs with cholangiolar differentiation (P=0.006, 
Figure 1A, C). As previously reported, the positive expression of N-cadherin and 
Neural cell adhesion molecule (NCAM) was associated with ICCs with 
cholangiolar differentiation (P<0.001 and P=0.018, respectively). However, the 
expression of vimentin was more prevalent in ICCs with bile ductal differentiation 
than ICCs with cholangiolar differentiation, although not statistically significant 
(P=0.124, Figure 2A-D). 
Because ICC with bile ductal differentiation were associated with the phenotype of 
tumor invasiveness (perineural invasion; Table 2), we also analyzed the expression 
of epithelial-mesenchymal transition (EMT) related genes. The protein expression 
level of zinc finger E-box binding homeobox 1 (ZEB1) was more prevalent in ICCs 
with bile ductal differentiation than in ICCs with cholangiolar differentiation 
(P=0.044, Figure 3A, B). TWIST was more frequently observed in ICCs with bile 
ductal differentiation than ICCs with cholangiolar differentiation, although not 
statistically significantly (P=0.308, Figure 3A, C). The differential expression of 
EMT-related genes was further confirmed by mRNA levels. The mRNA levels of 
SNAIL, ZEB1 were also significantly higher in ICCs with bile ductal differentiation 
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than ICCs with cholangiolar differentiation (P<0.001, for both) (Figure 3E, F). 
There was no significant difference in E-cadherin loss on immunostaining and 
mRNA level of zinc finger E-box binding homeobox 2 (ZEB2) according to 
cholangiolar differentiation (P=1.000, P=0.119, Figure 3D, G). 
 
Figure 1. Comparison of the expression of CRP and CLDN18 between ICCs 
with cholangiolar differentiation and ICCs with bile ductal differentiation. A) 
ICCs with cholangiolar differentiation showing CRP expression without CLDN18 
expression. In contrast, ICCs with bile ductal differentiation showing CLDN18 
expression without CRP expression. B) Comparison of CRP expression between 
ICCs with cholangiolar differentiation and those with bile ductal differentiation. C) 
Comparison of CLDN18 expression between ICCs with cholangiolar differentiation 
and those with bile ductal differentiation (Original magnification, x200). 
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Figure 2. Comparison of the expression of N-cadherin, NCAM and vimentin 
between ICCs with cholangiolar differentiation and ICCs with bile ductal 
differentiation. A) ICCs with cholangiolar differentiation showing strong N-
cadherin and NCAM expression. In contrast, ICCs with bile ductal differentiation 
showing strong vimentin expression. Comparison of B) N-cadherin, C) NCAM, and 
D) vimentin expression between ICCs with cholangiolar differentiation and those 
with bile ductal differentiation (Original magnification, x200). 
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Figure 3. Comparison of the expression of EMT related molecules between 
ICCs with cholangiolar differentiation and ICCs with bile ductal 
differentiation. A) Representative features of protein expression of ZEB1, TWIST, 
and E-cadherin in ICCs with cholangiolar differentiation and ICCs with bile ductal 
differentiation. Comparison of B) ZEB1, C) TWIST, and D) E-cadherin protein 
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expression between ICCs with cholangiolar differentiation and those with bile 
ductal differentiation. Box plot graphs demonstrating comparisons of E) SNAIL, F) 
ZEB1, G) ZEB2 mRNA levels between two groups (Original magnification, x200). 
 
4. Clinicopathological features according to cholangiolar or bile ductal 
differentiation markers 
 
ICCs were divided into two groups according to CRP protein expression status, and 
clinicopathological features were compared between CRP-positive and CRP-
negative groups (Table 4). CPR-positive ICCs demonstrated more frequent 
cholangiolar differentiation (P > 0.001). CRP-positive ICCs were associated with 
viral hepatitis (P=0.002), and less associated with ductal epithelial dysplasia 
(P=0.026), compared to CRP-negative ICCs. CRP-positive ICCs were lower CA19-
9 levels, compared to CRP-negative ICCs (P=0.002). Perinueral invasion was less 
frequent in CRP-positive ICCs than in CRP-negative ICCs (P=0.002).  
Next, we divided into two groups according to N-cadherin protein expression status, 
and clinicopathological features were compared N-cadherin positive and N-cadherin 
negative groups (Table 5). N-cadherin positive ICCs showed more frequent 
cholangiolar differentiation (P > 0.001). N-cadherin positive ICCs were less 
associated with hepatolithiasis and ductal epithelial dysplasia compared to N-
cadherin negative ICCs (P=0.046, P=0.005, respectively). Perinueral invasion was 
less frequent in N-cadherin positive ICCs than in N-cadherin negative ICCs 
(P=0.011). Furthermore, we divided into two groups according to CLDN18 protein 
expression status, and clinicopathological features were compared CLDN18-
positive and CLDN18-negative groups (Table 6). CLDN18-negative ICCs showed 
more frequent cholangiolar differentiation (P = 0.003) and more associated with 
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viral hepatitis compared to CLDN18- positive ICCs (P=0.004). 
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Table 4. Comparison of clinicopathologic features between CRP positive 
ICCs and CRP negative ICCs 
Clinicopathologic features 
CRP 
positive  
(n=19) 
CRP 
negative  
(n=121) 
P value* 
Age (years, median, IQR)  63 (55-70) 64 (56-69) 0.274 
Gender (Male, Female, %) 10 (53), 9 (47) 71 (59), 50 (41) 0.627 
Cholangiolar differentiation (present, %) 13 (68) 7 (6) <0.001 
Serum markers    
CA19-9 (U/mL, median, IQR) 10 (5.6-76.2) 28.5 (8.1-337) 0.002 
CEA (ng/mL, median, IQR) 2.1 (1.9-76.2) 2.2 (1.4-6.1) 0.614 
Alpha-fetoprotein (IU/mL,median, 
IQR) 
1.7 (1.4-4.9) 2.9 (2.2-5) 0.697 
PIVKA-II (mAU/mL, median, IQR) 38 (36-40) 25.5 (19-32) 0.065 
Tumoral pathology    
Tumor size (cm, median, IQR)  4.3 (3.6-5.1) 4.9 (2.9-6.5) 0.186 
Gross morphology (%) 
  
0.032 
     Mass forming 18 (95) 73 (60) 
 
     Periductal infiltrating 0 8 (7) 
 
     Intraductal growth 1 (5) 18 (15)  
     Mixed 0 22 (18)  
Differentiation (%) 
  
0.837 
     Well differentiation 6(35) 33 (29) 
 
     Moderate differentiation 9(53) 59 (52) 
 
     Poor differentiation 2 (12) 19 (17) 
 
     Undifferentiation 0 3 (2) 
 
Fibrous capsule formation (present, %) 1 (5) 1 (1) 0.256 
Microvessel invasion (present, %) 13 (68) 77 (64) 0.800 
Bile duct invasion (present, %) 4 (21) 46 (38) 0.200 
Serosal invasion (present, %) 15 (79) 84 (69) 0588 
Perineural invasion (present, %) 2 (11) 54 (47) 0.002 
Non-tumoral pathology    
Viral hepatitis (present, %) 9 (53) 18 (17) 0.002 
Hepatolithiasis (present, %) 1 (5) 21 (17) 0.308 
Ductal epithelial dysplasia (present, %) 1 (5) 35 (29) 0.026 
Abbreviations: IQR, interquartile range. 
*p-values were calculated by Fisher’s exact test, Pearson chi-square and Mann-Whitney U test. 
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Table 5. Comparison of clinicopathologic features between N-cadherin 
positive ICCs and N-cadherin negative ICCs 
Clinicopathologic features 
N-cadherin 
positive  
(n=31) 
N-cadherin 
negative  
(n=109) 
P value* 
Age (years, median, IQR)  59 (55-66) 65 (57-70) 0.101 
Gender (Male, Female, %) 16 (52), 15 (48) 67 (62), 42 (38) 0.408 
Cholangiolar differentiation (present, %) 11 (36) 8 (7) <0.001 
Serum markers    
CA19-9 (U/mL, median, IQR) 34 (7.6-383) 27 (8-291) 0.118 
CEA (ng/mL, median, IQR) 2.9 (1.7-4.9) 2.1 (1.3-5.8) 0.958 
Alpha-fetoprotein (IU/mL,median, 
IQR) 
1.6 (1.3-6) 3 (2.2-4.5) 0.905 
PIVKA-II (mAU/mL, median, IQR) 36 (25-42) 27 (20-34) 0.091 
Tumoral pathology    
Tumor size (cm, median, IQR)  5 (3.9-6.3) 4.5 (2.7-6) 0.318 
Gross morphology (%) 
  
0.009 
     Mass forming 28 (90) 63 (58) 
 
     Periductal infiltrating 0 8 (7) 
 
     Intraductal growth 1 (3) 18 (17)  
     Mixed 2 (7) 20 (18)  
Differentiation (%) 
  
0.430 
     Well differentiation 9 (31) 30 (29) 
 
     Moderate differentiation 13 (45) 55 (54) 
 
     Poor differentiation 7 (24) 14 (14) 
 
     Undifferentiation 0 3 (3) 
 
Fibrous capsule formation (present, %) 1 (3) 1 (1) 0.398 
Microvessel invasion (present, %) 20 (65) 71 (65) 1.000 
Bile duct invasion (present, %) 6 (19) 43 (40) 0.054 
Serosal invasion (present, %) 25 (81) 73 (67) 0.184 
Perineural invasion (present, %) 6 (20) 49 (48) 0.011 
Non-tumoral pathology    
Viral hepatitis (present, %) 7 (26) 20 (21) 0.601 
Hepatolithiasis (present, %) 1 (3) 21 (19) 0.046 
Ductal epithelial dysplasia (present, %) 2 (7) 34 (31) 0.005 
Abbreviations: IQR, interquartile range. 
*p-values were calculated by Fisher’s exact test, Pearson chi-square and Mann-Whitney U test. 
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Table 6. Comparison of clinicopathologic features between CLDN18 
positive ICCs and CLDN18 negative ICCs 
Clinicopathologic features 
CLDN18 
positive  
(n=56) 
CLDN18 
negative  
(n=84) 
P value* 
Age (years, median, IQR)  66 (58-70) 63 (55-68) 0.130 
Gender (Male, Female, %) 33 (59), 23 (41) 49 (58), 35 (42) 1.000 
Cholangiolar differentiation (present, %) 2 (4) 18 (21) 0.003 
Serum markers    
CA19-9 (U/mL, median, IQR) 22.5 (3.7-130) 37.6 (10-950) 0.875 
CEA (ng/mL, median, IQR) 1.8 (1.2-3.5) 3 (1.9-7.5) 0.365 
Alpha-fetoprotein (IU/mL,median, 
IQR) 
3 (2.2-4.5) 2.8 (1.7-5.2) 0.018 
PIVKA-II (mAU/mL, median, IQR) 27 (18-42) 28 (21-35) 0.524 
Tumoral pathology    
Tumor size (cm, median, IQR)  4.3 (2.7-6.3) 4.8 (3.2-6.0) 0.496 
Gross morphology (%) 
  
0.179 
     Mass forming 31 (55) 61 (73) 
 
     Periductal infiltrating 4 (7) 4 (5) 
 
     Intraductal growth 11 (20) 8 (9)  
     Mixed 10 (18) 11 (13)  
Differentiation (%) 
  
0.255 
     Well differentiation 17 (32) 23 (30) 
 
     Moderate differentiation 31 (57) 37 (47) 
 
     Poor differentiation 6 (11) 15 (19) 
 
     Undifferentiation 0 3 (4) 
 
Fibrous capsule formation (present, %) 0 2 (2) 0.515 
Microvessel invasion (present, %) 35 (63) 55 (66) 0.723 
Bile duct invasion (present, %) 22 (39) 27 (33) 0.471 
Serosal invasion (present, %) 35 (63) 63 (75) 0.134 
Perineural invasion (present, %) 25 (48) 22 (32) 0.428 
Non-tumoral pathology    
Viral hepatitis (present, %) 4 (8) 23 (30) 0.004 
Hepatolithiasis (present, %) 7 (13) 14 (17) 0.631 
Ductal epithelial dysplasia (present, %) 16 (29) 20 (24) 0.561 
Abbreviations: IQR, interquartile range. 
*p-values were calculated by Fisher’s exact test, Pearson chi-square and Mann-Whitney U test. 
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5. Comparison of prognosis between ICCs with cholangiolar differentiation 
and ICCs with bile ductal differentiation 
 
We evaluated the prognostic significance of the histologic subgroup, and their 
differentiation markers (CRP, N-cadherin and CLDN18). The ICCs with 
cholangiolar differentiation demonstrated significantly better overall survival when 
compared to ICCs with bile ductal differentiation (P=0.021). The CRP- or N-
cadherin positive ICCs, also showed significantly better survival when compared to 
those negative ones (P=0.011, P=0.041, respectively. Figure 4A). The cholangiolar 
differentiation, CRP and N-cadherin were not the significant prognostic factor for 
disease free survival in ICC patients (Figure 5A). Regarding the mass-forming ICC 
subgroup, the positive for ICCs with cholangiolar differentiation, CRP, or N-
cadherin were good prognostic factor for overall survival (P<0.05, for all, Figure 4B) 
and N-cadherin was prognostic factor for favorable disease-free survival (P=0.018, 
Figure 4C). However, CLDN18 was not significant prognostic factor for disease 
free-survival and overall survival in both ICC and mass-forming ICC subgroup 
(Figure 5B, C). 
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Figure 4. Kaplan–Meier’s plot analysis for overall and disease-free survival in 
ICCs. A) Survival curves showed better overall survival in ICCs with cholangiolar 
differentiation, CRP-positive, and N-cadherin positive expression. B) Kaplan-
Meier’s plot analysis showed better overall survival in ICCs with cholangiolar 
differentiation, CRP-positive, and N-cadherin positive patients with mass-forming 
gross morphology. C) Kaplan-Meier’s plot analysis showed better disease-free 
survival in ICCs N-cadherin positive expression patients with mass-forming gross 
morphology. 
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Figure 5. Kaplan–Meier curves for survival rates of ICC patients. A) Kaplan-
Meier curves for disease-free survival of patients with ICC showed according to 
cholangiolar differentiation, CRP-, and N-cadherin protein expression status. B) 
Kaplan Meier curves for overall survival of patients with ICC and mass-forming 
type ICC demonstrated according to the CLDN18 protein expression status. C) 
Kaplan Meier curves for disease-free survival of patients with ICC and mass-
forming type ICC demonstrated according to the CLDN18 protein expression status.   
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IV. DISCUSSION 
 
Cholangiocarcinoma is very heterongenous tumor in the points of etiology, 
morphology, cell –of-origin, and clinical features. 
Pathologically, ICC has various morphologies and is thus generally subclassified as 
two distinct groups; ICCs with cholangiolar differentiation and ICCs with bile 
ductal differentiation. These two groups have different characteristics not only in 
morphological features but in etiological and clinical features and immunophenotye. 
In the ICCs with cholangiolar differentiation, the morphology of the cholangiolar 
differentiation is similar to small bile duct or hepatic progenitor cells,
20
 while the 
ICCs with bile ductal differentiation is similar to large bile duct or pancreatic duct. 
In addition, the underlying liver disease is dependent upon subgroup, as the patient 
of viral hepatitis is commonly associated with, like HCC, the ICC with cholangiolar 
differentiation while the ICC with bile ductal differentiation is associated with 
hepatolithiasis. 
Also, pancreatic cancer markers, such as TFF1, AGR2 and S100P, were 
significantly expressed in ICCs with bile ductal differentiation, and these tumors 
showed significantly poor overall survival.
12,13
 This suggests that ICC shows the 
tumor heterogeneity in terms of embryological development as well as pathological 
features. In the present study, ICC with cholangiolar differentiation (14.1%) was 
frequently associated with clinicopathologic features, including less frequent 
perinueral invasion, and good differentiation. Fibrous capsule formation and lack of 
ductal epitherial dysplasia were more frequently observed. EMT-related proteins, 
such as ZEB1 were significantly less expressed in ICC with cholangiolar 
differentiation, and these tumors showed good prognosis. Therefore, ICC with 
cholangiolar differentiation was more closely related to less aggressive behavior. 
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Embryologically, at embryonic day (E)9.5, biliary trees and pancreas are originated 
from ventral endoderm.
21
 Together with extrahepatic biliary tree, pancreas arises 
from the ventral endoderm of the foregut at almost same time, whereas small 
intrahepatic biliary tree is originated from the hepatic stem cells. Hepatic stem cells 
in the canals of Hering differentiated into hepatoblasts and to hepatocytes or 
intrahepatic cholangiocytes.
20,22,23
 This suggests that extrahepatic bile duct and 
pancreatic duct have similar cellular origin. Contrary to these two types, small bile 
duct is thought to have a smilar origin to those of hepatoblast and hepatocyte, 
indicating that embryological origin of duct varies. 
By gene expression pattern, ICC can also be classified into inflammation group and 
proliferation group, associated with the former representing good prognosis and the 
latter representing poor. In this study, according to the result of microarray data, 
inflammation or good prognosis group is associated with cholangiolar 
differentiation, whereas proliferation or poor prognosis group with bile ductal 
differentiation, indicating that genomic and genetic characterization of ICC is 
highly associated with classification of histological subgroup.
17,18
 
With patient outcome for ICC with cholangiolar differentiation (liver-like CC) is 
better than that of ICC with bile ductal differentiation (pancreas cancer-like CC),
6
 
patient prognosis clearly can be divided based on the subclassification. According 
to the recent report, cholangiolocellular carcinoma (CLC) is a type of combined 
HCC-CC largely containing cells shaped similar to cholangiolar differentiation and 
features better prognosis than ICC with less lymph node metastasis and perineural 
invasion, which are well-known prognostic factors of CC.
24,25
 Because this 
subgroup of ICCs has been reported to show less aggressive behaviors, compared to 
ICC with bile duct differentiation, it is important that a suitable marker is developed 
30 
 
 
to facilitate its diagnosis. Indeed, it is thought that the expression of CRP and N-
cadherin may serve as a good prognostic marker.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
V. CONCLUSION 
 
In conclusion, ICC with cholangiolar differentiation and ICC with bile ductal 
differentiation are suggested to be distinct based on clinicopathological 
characteristics. ICC with cholangiolar differentiation is considered to be less 
aggressive type of ICC with better prognosis compared to ICC with bile ductal 
differentiation. CRP and N-cadherin are suggested to be good markers for 
cholangiolar differentiation. 
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ABSTRACT (IN KOREAN) 
 
담세관 분화와 담관 분화를 보이는  
담관상피암종의 임상병리학적 특성 비교 
 
<지도교수 박 영 년> 
 
연세대학교 대학원 의과학과 
 
고 정 은 
 
최근 간내 담관암에는 담세관 분화 및 담관 분화를 보이는 것이 있다고 
보고 되었으나, 그 임상병리학적 및 분자병리학적 특성에 대해서는 아직 
밝혀지지 않았다. 본 연구에서는 1997년부터 2013년까지의 세브란스병
원에서 수술받은 간내담관암 환자 142명을 선별하여 연구를 진행하였다. 
병리조직학적 검색 소견상 담세관 분화는 20 (14.1%)예에서 담관 분화
는 122 (85.9%)예에서 관찰되었다. 면역조직화학염색 및 실시간 중합효
소연쇄반응을 이용하여 c-reactive protein (CRP), claudin (CLDN18), 
N-cadherin, Neural cell adhesion molecule (NCAM), vimentin 그리고 상
피간엽이행 마커로 잘 알려진 zinc finger E-box binding homeobox1 
(ZEB1), zinc finger E-box binding homeobox2 (ZEB2), TWIST, SNAIL 
그리고 E-cadherin에 대한 발현과 임상병리학적 특성을 담세관 분화 및 
담관 분화를 보이는 두 그룹에서 비교하였다. 담세관 분화를 보이는 간내
담관암은 담관 분화가 있는 간내담관암 보다 여성의 발생이 높았고, B형 
또는 C형 만성간염과 연광성이 높았던 반면, 간내담석증과 담관상피이형
성 비율은 낮았다. (P < 0.05). 육안 소견상 담세관 분화를 보이는 간내
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담관암은 모두 (20/20, 10%) 종괴형성형의 소견을 보이는 반면, 담관 분
화가 있는 간내담관암은 72예 (72/122, 59%)가 종괴형성형이였다 (P = 
0.005). 또한 담세관 분화가 있는 간내담관암에서 신경주위침범이 담관 
분화가 있는 간내담관암보다 더 많이 관찰 되었다 (P = 0.013). CRP, 
N-cadherin그리고 NCAM의 단백질 발현은 담세관 분화가 있는 간내담
관암에서 높았고, CLDN18과 ZEB1의 단백질 발현은 담관 분화가 있는 
간내담관암에서 높았다 (P < 0.05). 반면, TWIST와 E-cadherin의 단백
질 발현은 두 군간에 차이가 없었다. SNAIL과 ZEB1의 mRNA발현은 담
관 분화가 있는 간내담관암 보다 담세관 분화가 있는 간내담관암에서 더 
낮게 발현 되었지만 (P < 0.05), ZEB2의 mRNA발현은 두 군간에 차이
가 없었다. 환자 추적관찰 분석결과 담세관 분화가 있는 환자 군이 담관 
분화가 있는 환자군 보다 예후가 더 좋았으며, CRP와 N-cadherin의 단
백질이 발현되는 환자 군이 그렇지 않은 환자 군보다 예후가 더 좋았다 
(P < 0.05). 이상의 소견으로 담세관 분화가 있는 간내담관암과 담관 분
화가 있는 간내담관암은 서로 다른 임상병리학적 및 분자병리학적 특성
을 가지며, 담세관 분화가 있는 간내담관암이 담관 분화가 있는 간내담관
암보다 종양의 생물학적 악성도가 적으며, 환자의 예후도 더 좋았다. 또
한, CRP, N-cadherin이 담세관 분화를 보이는 간내담관암의 좋은 마커로 
생각한다. 
 
핵심되는 말: 담관상피암종, 담세관 분화, 담관 분화, c-reactive protein, 
N-cadherin, 상피간엽이행 
